


**Limited Review Report**

To  
**The Board of Directors**  
**Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Fortis Malar Hospitals Limited ('the Company') for the quarter ended June 30, 2015 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", specified under Section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts), Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S.R. BATLIBOI & ASSOCIATES LLP**  
Chartered Accountants  
ICAI Firm registration number: 101049W



per **Aniruddh Sankaran**  
Partner  
Membership No.: 211107

Place : Chennai  
Date : July 30, 2015



**FORTIS MALAR HOSPITALS LIMITED**

Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi -110025  
**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2015**


**PART I** (Rs. in lakhs except EPS and shareholding data)

	Particulars	Standalone Quarter ended			Standalone year ended
		June 30, 2015 (unaudited)	March 31, 2015 (Audited)	June 30, 2014 (unaudited)	March 31, 2015 (Audited)
1	a) Income from Operations	3,005.88	3,079.57	2,831.67	11,763.92
	b) Other Operating income	12.73	(33.39)	25.92	28.65
	<b>Net Income from Operations</b>	<b>3,018.61</b>	<b>3,046.18</b>	<b>2,857.59</b>	<b>11,792.57</b>
2	a) Drugs and Consumables	707.60	735.31	685.09	2,755.35
	b) Employees Cost	408.21	382.48	387.44	1,547.42
	c) Professional Charges-Doctors	727.69	741.70	702.30	2,954.38
	d) Clinical Establishment Fee	454.79	449.02	433.47	1,762.34
	d) Net Depreciation and amortization	78.36	75.45	60.26	271.18
	e) Other Expenditure	578.02	499.79	477.64	2,020.35
	<b>Total Expenditure</b>	<b>2,954.67</b>	<b>2,883.75</b>	<b>2,746.20</b>	<b>11,311.02</b>
3	<b>Profit from operations before other income, finance costs &amp; exceptional items (1-2)</b>	<b>63.94</b>	<b>162.43</b>	<b>111.39</b>	<b>481.55</b>
4	Other Income	190.69	187.63	180.49	736.41
5	<b>Profit before Interest &amp; Exceptional Items (3 + 4)</b>	<b>254.63</b>	<b>350.06</b>	<b>291.88</b>	<b>1,217.96</b>
6	Finance Costs	9.19	9.31	10.96	50.88
7	<b>Profit from ordinary activities after Finance Cost but before Exceptional items and Tax (5 - 6)</b>	<b>245.44</b>	<b>340.75</b>	<b>280.92</b>	<b>1,167.08</b>
8	Exceptional Items	-	-	-	-
9	<b>Profit from ordinary activities before tax</b>	<b>245.44</b>	<b>340.75</b>	<b>280.92</b>	<b>1,167.08</b>
10	Tax expense	84.65	116.51	95.48	401.14
11	<b>Net Profit from ordinary activities after tax</b>	<b>160.79</b>	<b>224.24</b>	<b>185.44</b>	<b>765.94</b>
12	Extraordinary items	-	-	-	-
13	<b>Net Profit after tax</b>	<b>160.79</b>	<b>224.24</b>	<b>185.44</b>	<b>765.94</b>
14	Paid up Equity Share Capital (Face Value Rs.10 each)	1,860.95	1,860.95	1,860.95	1,860.95
15	Reserves excluding Revaluation Reserves	-	-	-	7,184.75
16	<b>Earnings Per Share (EPS) - Basic ( Rs.)</b>	<b>0.86</b>	<b>1.20</b>	<b>1.00</b>	<b>4.12</b>
17	<b>Earnings Per Share (EPS) - Diluted ( Rs.)</b>	<b>0.86</b>	<b>1.20</b>	<b>0.99</b>	<b>4.10</b>
		[Not Annualised]	[Not Annualised]	[Not Annualised]	[Annualised]

**PART II**

<b>A PARTICULARS OF SHAREHOLDING</b>					
1	<b>Public Shareholding</b>				
	- Number of Shares	6,841,857	6,841,857	6,841,857	6,841,857
	- Percentage of shareholding	36.80%	36.80%	36.80%	36.80%
2	<b>Promoters and promoters group Shareholding</b>				
	<b>a) Pledged / Encumbered</b>				
	- No. of shares	Nil	Nil	Nil	Nil
	- % of shares (as a % of total shareholding of promoter and promoter group)				
	- % of shares (as a % of total share capital of the company)				
	<b>b) Non-Encumbered</b>				
	- No. of shares	11,752,402	11,752,402	11,752,402	11,752,402
	- % of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- % of shares (as a % of total share capital of the company)	63.20%	63.20%	63.20%	63.20%
<b>B</b>	<b>INVESTOR COMPLAINTS</b>				
	<b>Particulars</b>	<b>Quarter ended June 30, 2015</b>			
	Pending at the beginning of the quarter	Nil			
	Received during the quarter	21			
	Disposed off during the quarter	21			
	Remaining unresolved at the end of the quarter	Nil			

- NOTES:**
- The above unaudited financial results have been reviewed by the Audit, Risk and Controls Committee, approved and taken on record by the Board of Directors in their meeting held on July 30, 2015.
  - The Company operates in one reportable segment in terms of Accounting Standard 17.
  - The figures of March 31, 2015 quarter are the balancing figures between the audited figures in respect of full financial year upto March 31, 2015 and the unaudited published year-to-date figures upto December 31, 2014, being the date of the end of the third quarter of the financial year which were subjected to limited review.
  - Previous period figures have been regrouped, wherever considered necessary.



Place: Chennai  
 Date : July 30, 2015

By Order of the Board  
 For and on Behalf of Board of Directors

*P. Raghunath*

P. Raghunath  
 Whole Time Director

**PRESS RELEASE**

**FORTIS MALAR REPORTS Q1FY16 REVENUE AT RS.30.19 CR, + 6%  
OPERATING PROFIT AT RS 1.42 CR,  
NET PROFIT AT RS 1.61 CR**

**Chennai, July 30, 2015:** Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended June 30, 2015.

**Commenting on the results Mr Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said,** “As part of our Company’s strategic thrust under the banner of “Lakshya programme”, our focus has been on continually raising the bar in the domain of medical excellence and improving clinical outcomes. All efforts are directed keeping in view the best interests of our patients and are aimed at positively influencing the health status of the community we seek to serve. In this regard the emergence and success of the Fortis Centre for Heart Failure and Transplant, as the premier institution in the region for the treatment of complex heart conditions, has been heartwarming. Continuing our journey of medical excellence in other vital medical areas we have now set up the Fortis Stroke Centre for Acute Ischemic Brain Stroke. We see this as an important landmark in the specialised and unparalleled treatment of Stroke in our Country.”

Fortis Malar is today very much an integral part of the city of Chennai and is carving a niche for itself as an exemplary medical institution founded on the sound Fortis Lakshya pillars of Clinical Excellence, Patient Centricity, Community Connect, Employee Connect and Investor Confidence.

**Financial Highlights for the Quarter (Q1FY2016)**

- Fortis Malar Hospitals reported operating revenue of Rs 30.19 Cr, a growth of 6% over the corresponding quarter of the previous year.
- Operating profit for the quarter stood at Rs 1.42 Cr compared to Rs. 1.72 Cr in the corresponding quarter of previous year.

- Net profit was at Rs 1.61 Cr compared to Rs.1.85 Cr reported during the corresponding period, last fiscal.
- Fortis Malar also witnessed growth in its key specialties, showing a markedly better performance in Cardiology, Orthopedics, Gastroenterology, Cosmetic & Plastic surgery and Health check programmes, which grew by 45%, 19%, 24%, 83% and 16% respectively.

### **Operational Highlights for the quarter**

- Fortis Malar launched “The Fortis Stroke centre’ in May 2015. This centre will facilitate in performing path breaking procedures to treat patients suffering from acute ischemic stroke.

The expert medical team at the hospital continued to perform high risk and rare surgeries.

During the quarter, the team performed the following complex surgeries:

- The expert cardiology team at Fortis Malar successfully performed its first combined Heart and Lung transplant.
- The Cardiology team at Fortis Malar successfully performed four heart transplants during the quarter, which included One HVAD (Heartware Ventricular Assist Device), and three transplants from donor human hearts.
- The Hospital also performed 8 renal transplants during the quarter.
- 24 knee replacement and 6 Hip replacement surgeries were performed at the hospital during the quarter.
- A 17 year old boy who had undergone epilepsy surgery elsewhere in 2008 was suffering from recurrent seizures. He had a right fronto-temporo-parietal opercula and insula resection. The patient underwent a Neuro surgery at Fortis Malar which lasted around 8 hours. He has since made a quick recovery and has been seizure free.
- A preterm male child with a low birth weight was transferred to our hospital for tertiary care. The child had serious congenital abnormalities for which multiple corrective

procedures were done in a single sitting 24 hours after birth. He had Esophageal Atresia for which an esophageal anastomosis was done, a Tracheo Esophageal fistula which was ligated, a Duodenal atresia for which Duodenojejunostomy was done, a Dysplastic kidney for which a nephrostomy was done and an Imperforate anus for which an Anoplasty was done. The child has made a miraculous recovery.

### **Corporate Social Responsibility**

Playing its part as a good corporate citizen, Fortis Malar has front ended programme that contribute to society. The hospital actively engaged with the local community meaningfully and organized:

- Health awareness talks, Health checkups and free cardiac camps at various corporate and Government organizations.
- Felicitated Blood Donors on the occasion of “World Blood Donor Day” and organized a health talk emphasizing the importance of blood donation.
- Provided Free CPR training sessions as part of the Heart saver program at the hospital and at various corporates.
- As part of its Community Connect initiative - “Sunday Conversations” were organized with specialists from Fortis Malar on topical health issues.

### **About Fortis Malar Hospitals Ltd**

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic

reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

### **About Fortis Healthcare Ltd**

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Singapore, Dubai, Mauritius and Sri Lanka with 54 healthcare facilities (including projects under development), approximately 10,000 potential beds and 270 diagnostic centres. In a global study of the 30 most technologically advanced hospitals in the world, its flagship, the Fortis Memorial Research Institute' (FMRI), was ranked No.2, by 'topmastersinhealthcare.com, and placed ahead of many other outstanding medical institutions in the world.

#### **DISCLAIMER**

*This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.*

#### **FOR MORE INFORMATION PLEASE CONTACT**

**Ms. P.S. Ramya Gourri**  
Executive PR & Communications  
Fortis Malar Hospitals Ltd  
Mobile: 8939831218  
[ramya.gourri@fortishealthcare.com](mailto:ramya.gourri@fortishealthcare.com)

**Sumit Jain**  
K2 Communications Pvt Ltd  
Mobile: 9886021715  
[Sumit.jain@k2communications.in](mailto:Sumit.jain@k2communications.in)